O’Melveny represented NYSE-listed WuXi PharmaTech (Cayman) Inc., a leading technology company serving the pharmaceutical, biotechnology, and medical device industries in the US and China, in its merger with a group of private equity investors and the company’s founders in a going-private transaction valued at US$3.3 billion. O’Melveny advised WuXi in connection with its initial public offering in 2007. Since then, O’Melveny has served as WuXi’s trusted outside counsel, representing the China-based R&D giant on numerous strategic business partnerships, joint ventures, acquisitions and new businesses as pursued growth successful initiatives on its way to becoming one of the leading open-access R&D capability and technology platform companies serving the pharmaceutical, biotechnology, and medical device industries. In order to obtain greater flexibility to focus on improving its long-term financial performance without the pressures created by the public equity market’s emphasis on short-term period-to-period financial performance, WuXi looked to O’Melveny to help it identify various strategic and other transactions that might better serve its aggressive growth strategy. Ultimately, O’Melveny advised WuXi on its “going private” transaction, a deal which is among the largest of its kind involving a Chinese-based US listed issuer and is representative of a recent trend of similar Chinese companies seeking to delist and deregister from the US markets in order to focus on private growth initiatives or explore a public offering on Chinese and Hong Kong exchanges.